MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms MAGELLAN
- Sponsors Bayer; Bayer HealthCare; Bayer Yakuhin; Janssen Research & Development
- 07 Apr 2022 Results of a pooled analysis (MAGELLAN and MARINER trials data) assessed that the patients with major bleeding but not those with non-major clinically relevant bleeding, would be at an increased risk of all-cause mortality published in the Circulation
- 23 Jan 2020 Results from MARINER and MAGELLAN trials published in the Thrombosis and Haemostasis.
- 18 Nov 2019 Results (N= 16,496), post hoc analysis of the data pooled from two trials (MAGELLAN and MARINER Trials) assessing the efficacy of the extended thromboprophylaxis post to hospital discharge presented at the American Heart Association Scientific Sessions 2019